Villepinte (France), December 6, 2017 (6pm CET) – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, takes note of the decision issued on November 28 by the Japanese Ministry of Health, Labour and Welfare (MHLW), regarding the mandatory revision of...
31/10/2017 Revenue at September 30, 2017
Revenue at September 30, 2017 €597.4 million at constant exchange rates: +5.1% Level of activity in line with expectation
20/09/2017 Guerbet Announces CE Mark for Vectorio®, An Innovative Medical Device for cTACE Procedures
Vectorio® will be presented at the upcoming radiology congresses
20/09/2017 FDA Approves Guerbet’s Dotarem® (gadoterate meglumine) for Pediatric Patients Younger than Two Years
Princeton (NJ, USA), September 5, 2017 – Guerbet LLC USA, the US affiliate of the global specialist in contrast products and solutions for medical imaging, announced today that the US Food and Drug Administration (FDA) has approved Dotarem® (gadoterate meglumine) for intravenous use with magnetic...
Guerbet is publishing revenue of €407.1 million for the 1st half-year of 2017, up 8.1% at current exchange rates and 5.6% at constant exchange rates (CER). In the second quarter, published revenue stood at €204.0 million, up 5.7% at current exchange rates and 3.8% at CER.
Guerbet announced today that it will phase out sales throughout the world of two products: Hexabrix® (meglumine and sodium ioxaglate) and Optimark® (gadoversetamide).
Villepinte, March 13, 2017 - Guerbet takes note of the recommendations issued by the Pharmacovigilance Risk Assessment Committee (PRAC), on Gadolinium-based Contrast Agents - procedure under Article 31 of Directive 2001/83/EC.